Liver cancer

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

Oncology

Interview at BIO 2025 with Pierre Arséne

Liver cancer diagnostic gets FDA breakthrough status, with P...

Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.

News

BMS gets another FDA okay for Opdivo/Yervoy combo

Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.

News

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category

News

Trial data raises questions about Imfinzi in liver cancer

AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects.

News

ASCO: TIGIT returns with Roche, Gilead data

A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two

MSD, Eisai abandon combination trial in liver cancer

Liver cancer diagnostic gets FDA breakthrough status, with P...

BMS gets another FDA okay for Opdivo/Yervoy combo

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

Trial data raises questions about Imfinzi in liver cancer

ASCO: TIGIT returns with Roche, Gilead data

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Liver cancer

Editor's Picks